Listed

Celldex Therapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2018

Filed with the SEC on May 10, 2018 and accepted by EDGAR at May 10, 2018, 08:19 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2018-01-01 to 2018-03-31$21.9mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2018-01-01 to 2018-03-31−$119.7mus-gaap:OperatingIncomeLoss
Income tax3 months2018-01-01 to 2018-03-31−$765.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2018-01-01 to 2018-03-31−$118.1mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Diluted EPS3 months2018-01-01 to 2018-03-31−$0.84us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow3 months2018-01-01 to 2018-03-31−$28.0mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2018-01-01 to 2018-03-31$259.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2018-03-31$39.8mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2018-03-31$131.0mus-gaap:AssetsCurrent
Total assetsAt period end2018-03-31$191.4mus-gaap:Assets
Current liabilitiesAt period end2018-03-31$24.0mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2018-03-31$57.3mus-gaap:Liabilities
Shareholders' equityAt period end2018-03-31$134.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001104659-18-031972. Last ingested by Listed: Nov 5, 2026, 19:04 ET. Listed shows no prices and gives no investment advice.